CAS No.: 641571-10-0
尼洛替尼 Catalog No. CSN11559
Synonyms: AMN107;US brand name: Tasigna;尼洛替尼
Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
靶点 Bcr-Abl
IC50:30nM- 描述
- 作用机制
- 细胞研究
- Cell Data
- 更多
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT00785785 - - Completed - - NCT01220648 Chronic Myeloid Leukemia Phase 1 Completed - Germany ... more >> Novartis Investigative Site Leipzig, Germany, 04103 Collapse << NCT01806571 Untreated Adult Acute Myeloid ... more >>Leukemia Collapse << Phase 2 Active, not recruiting April 18, 2020 United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << - 更多
- 参考文献
- [1] O'Hare T, Walters DK, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5.
- [2] Weisberg E, Manley PW, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb;7(2):129-41.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 641571-10-0 | 储存条件 |
|
|||||||||||||
| 分子式 | C28H22F3N7O | 运输 | 蓝冰 | |||||||||||||
| 分子量 | 529.52 | 别名 | AMN107;US brand name: Tasigna;尼洛替尼 | |||||||||||||
| 溶解度 |
|
动物实验配方 |
|
| Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
|---|
| 697 | - | Growth Inhibition Assay | - | IC50=11.2101 μM | SANGER |
| 769-P | - | Growth Inhibition Assay | - | IC50=19.6335 μM | SANGER |
| A101D | - | Growth Inhibition Assay | - | IC50=10.8923 μM | SANGER |
| A172 | - | Growth Inhibition Assay | - | IC50=25.7136 μM | SANGER |
| A204 | - | Growth Inhibition Assay | - | IC50=1.57205 μM | SANGER |
| A2058 | - | Growth Inhibition Assay | - | IC50=10.9245 μM | SANGER |
| A2780 | - | Growth Inhibition Assay | - | IC50=31.8358 μM | SANGER |
| A388 | - | Growth Inhibition Assay | - | IC50=8.38481 μM | SANGER |
| A427 | - | Growth Inhibition Assay | - | IC50=13.4972 μM | SANGER |
| A4-Fuk | - | Growth Inhibition Assay | - | IC50=13.4102 μM | SANGER |
| ACHN | - | Growth Inhibition Assay | - | IC50=9.23632 μM | SANGER |
| ACN | - | Growth Inhibition Assay | - | IC50=1.55077 μM | SANGER |
| AGS | - | Growth Inhibition Assay | - | IC50=13.0351 μM | SANGER |
| BALL-1 | - | Growth Inhibition Assay | - | IC50=19.6775 μM | SANGER |
| BB65-RCC | - | Growth Inhibition Assay | - | IC50=16.0241 μM | SANGER |
| BCPAP | - | Growth Inhibition Assay | - | IC50=9.02562 μM | SANGER |
| BE-13 | - | Growth Inhibition Assay | - | IC50=1.27416 μM | SANGER |
| BHT-101 | - | Growth Inhibition Assay | - | IC50=0.64263 μM | SANGER |
| BT-549 | - | Growth Inhibition Assay | - | IC50=18.4092 μM | SANGER |
| BV-173 | - | Growth Inhibition Assay | - | IC50=0.01089 μM | SANGER |
| C2BBe1 | - | Growth Inhibition Assay | - | IC50=32.2634 μM | SANGER |
| C32 | - | Growth Inhibition Assay | - | IC50=24.9576 μM | SANGER |
| CAL-33 | - | Growth Inhibition Assay | - | IC50=6.31359 μM | SANGER |
| CAL-85-1 | - | Growth Inhibition Assay | - | IC50=25.4577 μM | SANGER |
| CGTH-W-1 | - | Growth Inhibition Assay | - | IC50=0.6487 μM | SANGER |
| ChaGo-K-1 | - | Growth Inhibition Assay | - | IC50=29.6097 μM | SANGER |
| COLO-668 | - | Growth Inhibition Assay | - | IC50=8.59491 μM | SANGER |
| COLO-679 | - | Growth Inhibition Assay | - | IC50=7.98671 μM | SANGER |
| COLO-684 | - | Growth Inhibition Assay | - | IC50=34.3404 μM | SANGER |
| COLO-800 | - | Growth Inhibition Assay | - | IC50=39.3638 μM | SANGER |
| COR-L88 | - | Growth Inhibition Assay | - | IC50=34.0741 μM | SANGER |
| CTB-1 | - | Growth Inhibition Assay | - | IC50=8.87128 μM | SANGER |
| CTV-1 | - | Growth Inhibition Assay | - | IC50=5.48938 μM | SANGER |
| D-392MG | - | Growth Inhibition Assay | - | IC50=45.9256 μM | SANGER |
| D-423MG | - | Growth Inhibition Assay | - | IC50=8.83756 μM | SANGER |
| D-566MG | - | Growth Inhibition Assay | - | IC50=7.47155 μM | SANGER |
| DB | - | Growth Inhibition Assay | - | IC50=13.3256 μM | SANGER |
| DBTRG-05MG | - | Growth Inhibition Assay | - | IC50=23.8472 μM | SANGER |
| DEL | - | Growth Inhibition Assay | - | IC50=18.3172 μM | SANGER |
| DJM-1 | - | Growth Inhibition Assay | - | IC50=36.8049 μM | SANGER |
| DSH1 | - | Growth Inhibition Assay | - | IC50=11.7953 μM | SANGER |
| DU-4475 | - | Growth Inhibition Assay | - | IC50=27.1872 μM | SANGER |
| ECC10 | - | Growth Inhibition Assay | - | IC50=19.2475 μM | SANGER |
| EM-2 | - | Growth Inhibition Assay | - | IC50=0.0041 μM | SANGER |
| EoL-1-cell | - | Growth Inhibition Assay | - | IC50=0.000144 μM | SANGER |
| ES5 | - | Growth Inhibition Assay | - | IC50=13.0512 μM | SANGER |
| ES7 | - | Growth Inhibition Assay | - | IC50=18.1122 μM | SANGER |
| ES8 | - | Growth Inhibition Assay | - | IC50=43.3698 μM | SANGER |
| EW-11 | - | Growth Inhibition Assay | - | IC50=48.2348 μM | SANGER |
| EW-13 | - | Growth Inhibition Assay | - | IC50=8.32054 μM | SANGER |
| EW-18 | - | Growth Inhibition Assay | - | IC50=20.3802 μM | SANGER |
| EW-24 | - | Growth Inhibition Assay | - | IC50=25.962 μM | SANGER |
| EW-3 | - | Growth Inhibition Assay | - | IC50=12.9307 μM | SANGER |
| G-402 | - | Growth Inhibition Assay | - | IC50=4.31203 μM | SANGER |
| GAMG | - | Growth Inhibition Assay | - | IC50=43.4517 μM | SANGER |
| GCT | - | Growth Inhibition Assay | - | IC50=9.09831 μM | SANGER |
| GI-1 | - | Growth Inhibition Assay | - | IC50=14.1184 μM | SANGER |
| GI-ME-N | - | Growth Inhibition Assay | - | IC50=45.8952 μM | SANGER |
| GP5d | - | Growth Inhibition Assay | - | IC50=38.8653 μM | SANGER |
| H4 | - | Growth Inhibition Assay | - | IC50=26.4243 μM | SANGER |
| H9 | - | Growth Inhibition Assay | - | IC50=2.73793 μM | SANGER |
| HAL-01 | - | Growth Inhibition Assay | - | IC50=4.88242 μM | SANGER |
| HCC1187 | - | Growth Inhibition Assay | - | IC50=44.8262 μM | SANGER |
| HCC1419 | - | Growth Inhibition Assay | - | IC50=31.24 μM | SANGER |
| HCC1806 | - | Growth Inhibition Assay | - | IC50=2.74327 μM | SANGER |
| HCC2218 | - | Growth Inhibition Assay | - | IC50=13.5856 μM | SANGER |
| HCC2998 | - | Growth Inhibition Assay | - | IC50=48.6236 μM | SANGER |
| HCC70 | - | Growth Inhibition Assay | - | IC50=34.9514 μM | SANGER |
| HCE-T | - | Growth Inhibition Assay | - | IC50=18.8341 μM | SANGER |
| HCT-116 | - | Growth Inhibition Assay | - | IC50=27.4349 μM | SANGER |
| HDLM-2 | - | Growth Inhibition Assay | - | IC50=7.40149 μM | SANGER |
| HD-MY-Z | - | Growth Inhibition Assay | - | IC50=24.2362 μM | SANGER |
| HEC-1 | - | Growth Inhibition Assay | - | IC50=10.2804 μM | SANGER |
| H-EMC-SS | - | Growth Inhibition Assay | - | IC50=26.4114 μM | SANGER |
| HL-60 | - | Growth Inhibition Assay | - | IC50=10.6853 μM | SANGER |
| HLE | - | Growth Inhibition Assay | - | IC50=11.8839 μM | SANGER |
| HMV-II | - | Growth Inhibition Assay | - | IC50=0.74874 μM | SANGER |
| HOP-62 | - | Growth Inhibition Assay | - | IC50=1.82077 μM | SANGER |
| HOS | - | Growth Inhibition Assay | - | IC50=4.80282 μM | SANGER |
| HSC-3 | - | Growth Inhibition Assay | - | IC50=47.3608 μM | SANGER |
| HT-1080 | - | Growth Inhibition Assay | - | IC50=3.91775 μM | SANGER |
| HT-1197 | - | Growth Inhibition Assay | - | IC50=25.5319 μM | SANGER |
| HT-144 | - | Growth Inhibition Assay | - | IC50=42.0567 μM | SANGER |
| HT-29 | - | Growth Inhibition Assay | - | IC50=17.7889 μM | SANGER |
| HTC-C3 | - | Growth Inhibition Assay | - | IC50=25.3577 μM | SANGER |
| HuO-3N1 | - | Growth Inhibition Assay | - | IC50=40.108 μM | SANGER |
| HuO9 | - | Growth Inhibition Assay | - | IC50=6.73964 μM | SANGER |
| HuP-T3 | - | Growth Inhibition Assay | - | IC50=21.0852 μM | SANGER |
| IGROV-1 | - | Growth Inhibition Assay | - | IC50=6.47191 μM | SANGER |
| J82 | - | Growth Inhibition Assay | - | IC50=48.7242 μM | SANGER |
| JAR | - | Growth Inhibition Assay | - | IC50=2.92084 μM | SANGER |
| J-RT3-T3-5 | - | Growth Inhibition Assay | - | IC50=45.4315 μM | SANGER |
| JVM-3 | - | Growth Inhibition Assay | - | IC50=14.2656 μM | SANGER |
| K-562 | - | Growth Inhibition Assay | - | IC50=5.9036 μM | SANGER |
| KALS-1 | - | Growth Inhibition Assay | - | IC50=46.7257 μM | SANGER |
| KARPAS-299 | - | Growth Inhibition Assay | - | IC50=16.6203 μM | SANGER |
| KARPAS-45 | - | Growth Inhibition Assay | - | IC50=11.0635 μM | SANGER |
| KASUMI-1 | - | Growth Inhibition Assay | - | IC50=0.02413 μM | SANGER |
| KG-1 | - | Growth Inhibition Assay | - | IC50=31.7429 μM | SANGER |
| KM-H2 | - | Growth Inhibition Assay | - | IC50=47.6007 μM | SANGER |
| KMOE-2 | - | Growth Inhibition Assay | - | IC50=26.0915 μM | SANGER |
| KNS-62 | - | Growth Inhibition Assay | - | IC50=36.9438 μM | SANGER |
| KU812 | - | Growth Inhibition Assay | - | IC50=0.00248 μM | SANGER |
| KY821 | - | Growth Inhibition Assay | - | IC50=29.6433 μM | SANGER |
| KYSE-150 | - | Growth Inhibition Assay | - | IC50=20.7047 μM | SANGER |
| KYSE-520 | - | Growth Inhibition Assay | - | IC50=9.33482 μM | SANGER |
| L-363 | - | Growth Inhibition Assay | - | IC50=3.61107 μM | SANGER |
| LAMA-84 | - | Growth Inhibition Assay | - | IC50=0.0049 μM | SANGER |
| LB2241-RCC | - | Growth Inhibition Assay | - | IC50=1.02228 μM | SANGER |
| LB771-HNC | - | Growth Inhibition Assay | - | IC50=9.76497 μM | SANGER |
| LCLC-103H | - | Growth Inhibition Assay | - | IC50=5.77471 μM | SANGER |
| LoVo | - | Growth Inhibition Assay | - | IC50=48.1002 μM | SANGER |
| LOXIMVI | - | Growth Inhibition Assay | - | IC50=20.7586 μM | SANGER |
| LU-135 | - | Growth Inhibition Assay | - | IC50=44.0923 μM | SANGER |
| LU-139 | - | Growth Inhibition Assay | - | IC50=19.0458 μM | SANGER |
| LU-65 | - | Growth Inhibition Assay | - | IC50=26.0452 μM | SANGER |
| LXF-289 | - | Growth Inhibition Assay | - | IC50=19.8979 μM | SANGER |
| MDA-MB-361 | - | Growth Inhibition Assay | - | IC50=6.33699 μM | SANGER |
| MEG-01 | - | Growth Inhibition Assay | - | IC50=0.00828 μM | SANGER |
| MFE-280 | - | Growth Inhibition Assay | - | IC50=21.5679 μM | SANGER |
| MFM-223 | - | Growth Inhibition Assay | - | IC50=42.402 μM | SANGER |
| MHH-ES-1 | - | Growth Inhibition Assay | - | IC50=29.3685 μM | SANGER |
| MHH-PREB-1 | - | Growth Inhibition Assay | - | IC50=29.5505 μM | SANGER |
| ML-2 | - | Growth Inhibition Assay | - | IC50=49.4605 μM | SANGER |
| MLMA | - | Growth Inhibition Assay | - | IC50=10.0132 μM | SANGER |
| MMAC-SF | - | Growth Inhibition Assay | - | IC50=46.9952 μM | SANGER |
| MN-60 | - | Growth Inhibition Assay | - | IC50=13.5843 μM | SANGER |
| MOLT-4 | - | Growth Inhibition Assay | - | IC50=8.62353 μM | SANGER |
| Mo-T | - | Growth Inhibition Assay | - | IC50=23.9 μM | SANGER |
| MS-1 | - | Growth Inhibition Assay | - | IC50=7.11953 μM | SANGER |
| MSTO-211H | - | Growth Inhibition Assay | - | IC50=27.6255 μM | SANGER |
| MV-4-11 | - | Growth Inhibition Assay | - | IC50=13.8137 μM | SANGER |
| NB14 | - | Growth Inhibition Assay | - | IC50=31.0446 μM | SANGER |
| NB7 | - | Growth Inhibition Assay | - | IC50=0.13439 μM | SANGER |
| NBsusSR | - | Growth Inhibition Assay | - | IC50=29.9904 μM | SANGER |
| NCI-H1092 | - | Growth Inhibition Assay | - | IC50=23.2843 μM | SANGER |
| NCI-H1304 | - | Growth Inhibition Assay | - | IC50=30.5716 μM | SANGER |
| NCI-H1666 | - | Growth Inhibition Assay | - | IC50=35.8253 μM | SANGER |
| NCI-H1693 | - | Growth Inhibition Assay | - | IC50=16.3802 μM | SANGER |
| NCI-H1703 | - | Growth Inhibition Assay | - | IC50=1.1887 μM | SANGER |
| NCI-H1755 | - | Growth Inhibition Assay | - | IC50=18.5723 μM | SANGER |
| NCI-H1770 | - | Growth Inhibition Assay | - | IC50=34.961 μM | SANGER |
| NCI-H1792 | - | Growth Inhibition Assay | - | IC50=49.8518 μM | SANGER |
| NCI-H1993 | - | Growth Inhibition Assay | - | IC50=22.4971 μM | SANGER |
| NCI-H2009 | - | Growth Inhibition Assay | - | IC50=29.1431 μM | SANGER |
| NCI-H2029 | - | Growth Inhibition Assay | - | IC50=14.2727 μM | SANGER |
| NCI-H2030 | - | Growth Inhibition Assay | - | IC50=49.7117 μM | SANGER |
| NCI-H209 | - | Growth Inhibition Assay | - | IC50=29.8366 μM | SANGER |
| NCI-H2228 | - | Growth Inhibition Assay | - | IC50=29.458 μM | SANGER |
| NCI-H2342 | - | Growth Inhibition Assay | - | IC50=24.6767 μM | SANGER |
| NCI-H28 | - | Growth Inhibition Assay | - | IC50=31.9861 μM | SANGER |
| NCI-H292 | - | Growth Inhibition Assay | - | IC50=27.9617 μM | SANGER |
| NCI-H358 | - | Growth Inhibition Assay | - | IC50=25.3943 μM | SANGER |
| NCI-H446 | - | Growth Inhibition Assay | - | IC50=28.2105 μM | SANGER |
| NCI-H510A | - | Growth Inhibition Assay | - | IC50=48.1871 μM | SANGER |
| NCI-H630 | - | Growth Inhibition Assay | - | IC50=19.9378 μM | SANGER |
| NCI-H69 | - | Growth Inhibition Assay | - | IC50=22.4299 μM | SANGER |
| NCI-H720 | - | Growth Inhibition Assay | - | IC50=12.6801 μM | SANGER |
| NCI-N87 | - | Growth Inhibition Assay | - | IC50=11.7731 μM | SANGER |
| NCI-SNU-1 | - | Growth Inhibition Assay | - | IC50=3.40092 μM | SANGER |
| NCI-SNU-5 | - | Growth Inhibition Assay | - | IC50=39.6916 μM | SANGER |
| NKM-1 | - | Growth Inhibition Assay | - | IC50=0.9015 μM | SANGER |
| no-11 | - | Growth Inhibition Assay | - | IC50=41.7354 μM | SANGER |
| NOS-1 | - | Growth Inhibition Assay | - | IC50=2.87102 μM | SANGER |
| NUGC-3 | - | Growth Inhibition Assay | - | IC50=8.53582 μM | SANGER |
| NY | - | Growth Inhibition Assay | - | IC50=6.53599 μM | SANGER |
| ONS-76 | - | Growth Inhibition Assay | - | IC50=42.8018 μM | SANGER |
| OVCAR-4 | - | Growth Inhibition Assay | - | IC50=33.4848 μM | SANGER |
| QIMR-WIL | - | Growth Inhibition Assay | - | IC50=22.0478 μM | SANGER |
| Ramos-2G6-4C10 | - | Growth Inhibition Assay | - | IC50=6.66931 μM | SANGER |
| RD | - | Growth Inhibition Assay | - | IC50=39.5258 μM | SANGER |
| RH-1 | - | Growth Inhibition Assay | - | IC50=23.5357 μM | SANGER |
| RKO | - | Growth Inhibition Assay | - | IC50=17.6433 μM | SANGER |
| RPMI-8226 | - | Growth Inhibition Assay | - | IC50=7.28287 μM | SANGER |
| RS4-11 | - | Growth Inhibition Assay | - | IC50=2.90623 μM | SANGER |
| RVH-421 | - | Growth Inhibition Assay | - | IC50=5.77536 μM | SANGER |
| SBC-1 | - | Growth Inhibition Assay | - | IC50=4.90907 μM | SANGER |
| SBC-5 | - | Growth Inhibition Assay | - | IC50=32.8511 μM | SANGER |
| SCC-4 | - | Growth Inhibition Assay | - | IC50=41.2137 μM | SANGER |
| SJRH30 | - | Growth Inhibition Assay | - | IC50=38.7341 μM | SANGER |
| SK-MEL-1 | - | Growth Inhibition Assay | - | IC50=3.43029 μM | SANGER |
| SK-MEL-2 | - | Growth Inhibition Assay | - | IC50=26.0312 μM | SANGER |
| SK-MEL-24 | - | Growth Inhibition Assay | - | IC50=7.63392 μM | SANGER |
| SK-MEL-28 | - | Growth Inhibition Assay | - | IC50=40.6435 μM | SANGER |
| SK-MEL-3 | - | Growth Inhibition Assay | - | IC50=40.5932 μM | SANGER |
| SK-MEL-30 | - | Growth Inhibition Assay | - | IC50=37.8737 μM | SANGER |
| SK-NEP-1 | - | Growth Inhibition Assay | - | IC50=4.83191 μM | SANGER |
| SK-OV-3 | - | Growth Inhibition Assay | - | IC50=21.8408 μM | SANGER |
| SK-UT-1 | - | Growth Inhibition Assay | - | IC50=40.5674 μM | SANGER |
| SW1116 | - | Growth Inhibition Assay | - | IC50=39.2805 μM | SANGER |
| SW1573 | - | Growth Inhibition Assay | - | IC50=25.7785 μM | SANGER |
| SW954 | - | Growth Inhibition Assay | - | IC50=34.0752 μM | SANGER |
| SW982 | - | Growth Inhibition Assay | - | IC50=3.64169 μM | SANGER |
| T-24 | - | Growth Inhibition Assay | - | IC50=43.4369 μM | SANGER |
| T98G | - | Growth Inhibition Assay | - | IC50=3.01313 μM | SANGER |
| TE-1 | - | Growth Inhibition Assay | - | IC50=45.1654 μM | SANGER |
| TE-12 | - | Growth Inhibition Assay | - | IC50=14.6046 μM | SANGER |
| TE-5 | - | Growth Inhibition Assay | - | IC50=22.4965 μM | SANGER |
| TI-73 | - | Growth Inhibition Assay | - | IC50=29.4001 μM | SANGER |
| TYK-nu | - | Growth Inhibition Assay | - | IC50=19.9315 μM | SANGER |
| UACC-257 | - | Growth Inhibition Assay | - | IC50=17.0582 μM | SANGER |
| UM-UC-3 | - | Growth Inhibition Assay | - | IC50=8.43956 μM | SANGER |
| VA-ES-BJ | - | Growth Inhibition Assay | - | IC50=32.31 μM | SANGER |
| WM-115 | - | Growth Inhibition Assay | - | IC50=15.5683 μM | SANGER |
| YH-13 | - | Growth Inhibition Assay | - | IC50=35.92 μM | SANGER |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
|---|
| NCT00785785 | - | - | Completed | - | - |
| NCT01220648 | Chronic Myeloid Leukemia | Phase 1 | Completed | - | Germany ... more >> Novartis Investigative Site Leipzig, Germany, 04103 Collapse << |
| NCT01806571 | Untreated Adult Acute Myeloid ... more >>Leukemia Collapse << | Phase 2 | Active, not recruiting | April 18, 2020 | United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << |
| NCT00702403 | Accelerated Phase Chronic Myel... more >>ogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remission Blastic Phase Chronic Myelogenous Leukemia Childhood Acute Lymphoblastic Leukemia in Remission Childhood Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia Philadelphia Positive Adult Acute Lymphoblastic Leukemia Philadelphia Positive Childhood Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Relapsing Chronic Myelogenous Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Collapse << | Phase 1 Phase 2 | Completed | - | United States, California ... more >> Stanford University Hospitals and Clinics Stanford, California, United States, 94305 United States, Florida H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium Tampa, Florida, United States, 33612 H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
| NCT01110668 | Gastrointestinal Stromal Tumor | Phase 2 | Completed | - | Turkey ... more >> Novartis Investigative Site Adana, Turkey Novartis Investigative Site Ankara, Turkey Novartis Investigative Site Istanbul, Turkey Novartis Investigative Site Izmir, Turkey Collapse << |
| NCT00785785 | Gastrointestinal Stromal Tumor... more >> (GIST) Collapse << | Phase 3 | Completed | - | - |
| NCT00441155 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 1 | Completed | - | United States, Massachusetts ... more >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 France Novartis Investigative Site Lyon Cedex, France, 69373 Italy Novartis Investigative Site Milano, MI, Italy, 20133 Collapse << |
| NCT00702403 | - | - | Completed | - | - |
| NCT02174445 | Chronic Myeloid Leukemia | Phase 3 | Suspended(very slow recruitmen... more >>t rate and a lot of pat. didn't fulfil BCR-ABL requirements) Collapse << | June 2019 | Germany ... more >> Universitätsklinikum Aachen Aachen, Germany, 52074 Praxis Dr. Bruder / Dr. Heinrich / Prof. Bangerter Augsburg, Germany, 86150 Universitätsklinikum Bonn Bonn, Germany, 53105 Gemeinschaftspraxis Dresden, Germany, 01307 Praxis Dr. Hauch Erfurt, Germany, 99084 Internistische Schwerpunktpraxis Erlangen oncosearch Erlangen, Germany, 91052 Praxis für Hämatologie/Onkologie Dres. Rudolph, Sengpiel, von Verschuer Essen, Germany, 45136 University Medical Center Freiburg, Germany, 79106 Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany, 20246 Universitätsklinikum Jena Jena, Germany, 07747 Universitätsklinik Köln Köln, Germany, 50937 Gemeinschaftspraxis Hämatologie/Onkologie Magdeburg, Germany, 39104 Klinikum Mannheim GmbH Universitätsklinikum Mannheim, Germany, 68167 Überörtliche Gemeinschaftspraxis Hämato-Onkologie Pasing/Fürstenfeldbruck Munich, Germany, 81241 Klinikum rechts der Isar, Technische Universität München München, Germany, 81675 Onkologische Praxis Oldenburg Oldenburg, Germany, 26121 Medizinische Statistik Saarbrücken, GbR Saarbrucken, Germany, 66113 Universitätsklinikum Ulm Ulm, Germany, 89081 Collapse << |
| NCT01294618 | Chronic Myelogenous Leukemia | Phase 2 | Completed | - | France ... more >> Hospices Civils de Lyon Lyon, France, 69003 Collapse << |
| NCT01126892 | Chronic Myeloid Leukemia | Phase 3 | Completed | - | Colombia ... more >> Hospital San José, Bogotá, Colombia Bogota, Colombia Venezuela Banco Municipal de Sangre Caracas, Venezuela Collapse << |
| NCT02627677 | Chronic Phase Chronic Myeloid ... more >>Leukemia Collapse << | Phase 3 | Active, not recruiting | December 31, 2022 | Belgium ... more >> Cliniques Universitaire Saint-Luc (Site 058) Bruxelles, Belgium, 1200 Collapse << |
| NCT01289054 | - | - | Completed | - | United States, North Carolina ... more >> INC Research, LLC Wilmington, North Carolina, United States, 28405 Collapse << |
| NCT01279473 | Chronic Myelogenous Leukemia ... more >> Acute Lymphoblastic Leukemia Collapse << | Phase 1 Phase 2 | Completed | - | Japan ... more >> Novartis Investigative Site Aichi, Japan Collapse << |
| NCT01077544 | Chronic Myeloid Leukemia ... more >> Acute Lymphoblastic Leukemia Collapse << | Phase 1 | Completed | - | United States, Illinois ... more >> Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie Chicago, Illinois, United States, 60611 Brazil Novartis Investigative Site Barretos, SP, Brazil, 14784-400 Novartis Investigative Site Sao Paulo, SP, Brazil Novartis Investigative Site São Paulo, SP, Brazil, 08270-070 France Novartis Investigative Site Bordeaux, Aquitaine, France, 33076 Novartis Investigative Site Lille cedex, France, 59037 Novartis Investigative Site Paris, France, 75571 Novartis Investigative Site Poitiers, France, 86021 Italy Novartis Investigative Site Monza, MB, Italy, 20900 Novartis Investigative Site Padova, PD, Italy, 35128 Novartis Investigative Site Roma, RM, Italy, 00161 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 110 744 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1081 HV Novartis Investigative Site Rotterdam, Netherlands, 3015 GJ Russian Federation Novartis Investigative Site Moscow, Russian Federation, 117997 United Kingdom Novartis Investigative Site Sutton, Surrey, United Kingdom, SM2 5PT Novartis Investigative Site Birmingham, United Kingdom, B4 6NH Novartis Investigative Site Bristol, United Kingdom, BS2 8BJ Collapse << |
| NCT00802841 | Chronic Myelogenous Leukemia | Phase 3 | Completed | - | - |
| NCT00644878 | Chronic Myelogenous Leukemia -... more >> Chronic Phase Collapse << | Phase 4 | Completed | - | United States, California ... more >> USC Norris Cancer Center Jane Anne Nohl Los Angeles, California, United States, 90033 United States, Florida Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States, 33138 United States, Georgia Georgia Health Sciences University Dept. of MCG Augusta, Georgia, United States, 30912 United States, Idaho Kootenai Medical Center Dept.ofKootenai Med.Ctr. Coeur d'Alene, Idaho, United States, 83814 United States, Indiana Indiana Blood and Marrow Institute Beach Grove, Indiana, United States, 46107 United States, Iowa University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic Iowa City, Iowa, United States, 52242 United States, Louisiana LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center New Orleans, Louisiana, United States, 70115 United States, Maryland St. Agnes Hospital Baltimore, Maryland, United States, 21229 United States, New York Montefiore Medical Center Medical Center Bronx, New York, United States, 10467 SUNY Upstate Medical Center Syracuse, New York, United States, 13210 Westchester Medical Center Munger Pavillion (2) Valhalla, New York, United States, 10595 United States, North Carolina Wake Forest University Baptist Medical Center Hematology and Oncology Winston-Salem, North Carolina, United States, 27157 United States, South Carolina Cancer Centers of the Carolinas Greenville, South Carolina, United States, 29615 United States, Tennessee University of Tennessee Cancer Institute Cancer Institute Memphis, Tennessee, United States, 38104 United States, Texas South Texas Institute of Cancer S. Tex Inst.- Corpus Christi Corpus Christi, Texas, United States, 78405 Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr Houston, Texas, United States, 77030 United States, Utah Central Utah Clinic Central Utah Clinic (7) Provo, Utah, United States, 84604 United States, Wisconsin Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial Milwaukee, Wisconsin, United States, 53226 Collapse << |
| NCT01077544 | - | - | Completed | - | - |
| NCT01774630 | Leukemia, Myelogenous, Chronic... more >>, BCR-ABL Positive Collapse << | Phase 2 | Recruiting | April 2020 | France ... more >> CHU Angers Recruiting Angers, France, 49033 Contact: Martine GARDEMBAS, MD Principal Investigator: Martine GARDEMBAS, MD Institut Bergonié Not yet recruiting Bordeaux, France, 33076 Contact: Gabriel ETIENNE, Dr G.Etienne@bordeaux.unicancer.fr Principal Investigator: Gabriel ETIENNE, Dr Sub-Investigator: Josy REIFFERS, Pr Sub-Investigator: François-Xavier MAHON, Pr Sub-Investigator: Anna SCHMITT, Dr Chu Estaing Not yet recruiting Clermont- Ferrand, France, 63003 Contact: Marc BERGER, MD, PhD Principal Investigator: Marc BERGER, MD,PhD Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B Recruiting Le Chesnay, France, 78157 Contact: Philippe ROUSSELOT, Pr prousselot@ch-versailles.fr Principal Investigator: Philippe ROUSSELOT, Pr Hôpital Claude Huriez, Service des Maladies du Sang Not yet recruiting Lille, France, 59037 Contact: Marie-Pierre NOEL, Dr mp-noel@chru-lille.fr Principal Investigator: Marie-Pierre NOEL, Dr Sub-Investigator: Valérie COITEUX, Dr Sub-Investigator: Nathalie CAMBIER, Dr Institut Paoli Calmette, Service Hématologie 3 Not yet recruiting Marseille, France, 13273 Contact: Aude CHARBONNIER, Dr charbonniera@marseille.fnclcc.fr Principal Investigator: Aude CHARBONNIER, Dr Sub-Investigator: Norbert VEY, Dr Sub-Investigator: Thomas PREBET, Dr Sub-Investigator: Jerôme REY, Dr Sub-Investigator: Anne ETIENNE, Dr Sub-Investigator: Evelyne D'INCAN, Dr CHU Hôtel Dieu, Service d'Hémato-Cancérologie Not yet recruiting Nantes, France, 44035 Contact: Viviane DUBRUILLE, Dr viviane.dubruille@chu-nantes.fr Principal Investigator: Viviane DUBRUILLE, Dr Sub-Investigator: Béatrice MAHE, Dr Sub-Investigator: CLAVERT Aline, Dr Sub-Investigator: Nicolas BLIN, Dr CHU de Nice, Service Hématologie Clinique Recruiting Nice, France, 06202 Contact: Laurence LEGROS, Dr legros.l@chu-nice.fr Principal Investigator: Laurence LEGROS, Dr Sub-Investigator: Jean-Michel KARSENTI, Dr Hôpital Saint Louis, Service des Maladies du Sang Not yet recruiting Paris, France, 75475 Contact: Philippe ROUSSELOT, Pr philippe.rousselot@chu-stlouis.fr Principal Investigator: Philippe ROUSSELOT, Pr Sub-Investigator: Delphine REA, Dr Hôpital Necker-Enfants Malades, Service d'Hématologie Not yet recruiting Paris, France, 75743 Contact: Bruno VARET, Pr bruno.varet@nck.aphp.fr Principal Investigator: Bruno VARET, Pr Sub-Investigator: Agnès BUZYN, Pr Sub-Investigator: Felipe SUAREZ, Dr Hôpital Haut Lévêque, Service Hématologie Recruiting Pessac, France, 33604 Contact: François-Xavier MAHON, Pr Francois-Xavier.Mahon@umr5540.u-bordeaux2.fr Principal Investigator: François-Xavier MAHON, Pr Sub-Investigator: Gérald MARIT, Pr Centre Hospitalier Lyon Sud, Service Hématologie Recruiting Pierre Benite, France, 69495 Contact: Franck NICOLINI, Dr franck.nicolini@chu-lyon.fr Principal Investigator: Franck NICOLINI, Dr Sub-Investigator: Mauricette MICHALLET, Pr Sub-Investigator: Xavier THOMAS, Dr Sub-Investigator: Fiorenza BARACCO, Dr Sub-Investigator: Hélène LABUSSIERE, Dr Sub-Investigator: Marie DETRAIT, Dr Sub-Investigator: Youcef CHELGHOUM, Dr Sub-Investigator: Sophie DUCASTELLE, Dr CHRU de Poitiers Not yet recruiting Poitiers, France, 86021 Contact: François GUILHOT, Md, PhD Principal Investigator: François GUILHOT, Md, PhD CH d'Annecy Recruiting Pringy, France, 74374 Contact: Pascale CONY-MAKHOUL, Dr pconymakhoul@ch-annecy.fr Principal Investigator: Pascale CONY-MAKHOUL, Dr Sub-Investigator: Bernadette CORRONT, Dr Hôpital Pontchaillou Recruiting Rennes, France, 35033 Contact: Martine ESCOFFRE-BARBE, Dr martine.escoffre-barbe@chu-rennes.fr Principal Investigator: Martine ESCOFFRE-BARBE, Dr Sub-Investigator: Bernard Marc, Dr Sub-Investigator: Charles DAURIAC, Dr Sub-Investigator: Stanislas NIMUBONA, Dr Sub-Investigator: Xavier CAHU, Dr Sub-Investigator: Thierry LAMY DE LA CHAPELLE, Dr Sub-Investigator: Roch HOUOT, Dr Sub-Investigator: Sophie DE GUIBERT, Dr CHU de Toulouse, Service d'Hématologie Recruiting Toulouse, France, 31059 Contact: Françoise RIGAL-HUGUET, Dr huguet.f@chu-toulouse.fr Sub-Investigator: Lucie OBERIC, Dr Sub-Investigator: Guy LAURENT, Pr Sub-Investigator: Christian RECHER, Pr Sub-Investigator: Anne HUYNH, Dr Sub-Investigator: Loïc YSEBAERT, Dr Principal Investigator: Françoise RIGAL-HUGUET, Dr CHU de Tours Not yet recruiting Tours, France, 37044 Contact: Emmanuel GYAN, MD Principal Investigator: Emmanuel GYAN, MD CH Valence Recruiting Valence, France, 26953 Contact: Jixing LIU, MD Principal Investigator: Jixing LIU, MD CHU Brabois, Service de Médecine A Not yet recruiting Vandoeuvre Les Nancy, France, 54500 Contact: Agnès-Paule GUERCI, Dr a.guerci@chu-nancy.fr Principal Investigator: Angès-Paule GUERCI, Dr Collapse << |
| NCT00418769 | Healthy | Phase 1 | Completed | - | - |
| NCT00802841 | - | - | Completed | - | - |
| NCT01844765 | Leukemia Leuk... more >>emia,Pediatric Leukemia, Myleiod Leukemia, Mylegenous, Chronic Leukemia, Mylegenous, Accelerated BCR-ABL Positive Myeloproliferative Disorder Bone Marrow Disease Hematologic Diseases Neoplastic Processes Imatinib Dasatinib Enzyme Inhibitor Protein Kinase Inhibitor Collapse << | Phase 2 | Active, not recruiting | October 7, 2020 | - |
| NCT01744665 | CML | Phase 2 | Active, not recruiting | February 1, 2021 | - |
| NCT01368523 | Chronic Myelogenous Leukemia | Phase 4 | Completed | - | Poland ... more >> Novartis Investigative Site Gdansk, Poland Novartis Investigative Site Poznan, Poland Novartis Investigative Site Warsaw, Poland Collapse << |
| NCT01168050 | Malignant Skin Melanoma T0 ... more >> Stage III Melanoma Stage IV Melanoma Amplification Collapse << | Phase 2 | Unknown | December 2013 | France ... more >> Hôpital Saint-Louis Recruiting Paris, France, 75010 Contact: Celeste Lebbe, MD, PhD celeste.lebbe@sls.aphp.fr Principal Investigator: Celeste Lebbe, MD, PhD Collapse << |
| NCT01535391 | Chronic Myeloid Leukemia | Phase 3 | Completed | - | Italy ... more >> Azienda Ospedaliera Nuovo Ospedale "Torrette" Ancona, Italy S.G. Moscati Hospital Avellino, Italy Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi Bologna, Italy, 40138 USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia Brescia, Italy, 25123 Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" Catania, Italy Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia Catanzaro, Italy Sezione di Ematologia e Fisiopatologia delle Emostasi - Azienda Ospedaliera - Arcispedale S. Anna Ferrara, Italy Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria Foggia, Italy Clinica Ematologica - DiMI - Università degli Studi di Genova Genova, Italy Divisione Ematologia 1 - Azienda Ospedaliera Universitaria "San Martino" Genova, Italy U.O. di Ematologia- Ospedale dell'Angelo - Mestre Mestre, Italy U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele Milano, Italy Centro Oncologico Modenese - Dipartimento di Oncoematologia Modena, Italy Università degli Studi di Padova - Ematologia ed Immunologia Clinica Padova, Italy Ospedale Cervello Palermo, Italy, 90146 Azienda Ospedaliera Universitaria - Policlinico Paolo Giaccone Palermo, Italy Div. di Ematologia di Muraglia -CTMO Ospedale San Salvatore Pesaro, Italy Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza Piacenza, Italy Dipartimento Oncologico - Ospedale S.Maria delle Croci Ravenna, Italy Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli" Reggio Calabria, Italy Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova Reggio Emilia, Italy Ospedale "Infermi" Rimini, Italy IRCCS Centro di riferimento Oncologico di Basilicata Rionero in Vulture, Italy Complesso Ospedaliero S. Giovanni Addolorata Roma, Italy Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma "Sapienza" Roma, Italy U.O.C. Ematologia Ospedale S. Eugenio Roma, Italy Università degli Studi Policlinico di Tor Vergata Roma, Italy Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo, Italy U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte" Siena, Italy U.O.C. di Ematolgia - A.O. " SS Annunziata" - P.O. S.G. Moscati Taranto, Italy SCDO Ematologia 2 AOU S.Giovanni Battista Torino, Italy Azienda USL 9 Treviso - U.O. di Ematologia Treviso, Italy, 31100 Clinica Ematologica - Policlinico Universitario Udine, Italy Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi Verona, Italy Collapse << |
| NCT02709083 | Chronic Myelogenous Leukemia ... more >> Chronic Myeloid Leukemia Leukemia Collapse << | Phase 2 | Terminated(Original principal ... more >>investigator left institution) Collapse << | - | United States, Georgia ... more >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 Collapse << |
| NCT02709083 | - | - | Terminated(Original principal ... more >>investigator left institution) Collapse << | - | - |
| NCT00418626 | Healthy | Phase 1 | Completed | - | United States, Virginia ... more >> Richmond, Virginia, United States, 23249 Collapse << |
| NCT00418756 | Healthy | Phase 1 | Completed | - | - |
| NCT01289028 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 3 | Completed | - | Germany ... more >> Novartis Investigative Site Bad Saarow, Germany, 155226 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Duesseldorf, Germany, 40479 Novartis Investigative Site Essen, Germany, 45122 Novartis Investigative Site Frankfurt, Germany, 60488 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Halle/'Saale, Germany, 06120 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Mannheim, Germany, 68167 Novartis Investigative Site Muenchen, Germany, 81377 Novartis Investigative Site Muenchen, Germany, 81675 Novartis Investigative Site Ulm, Germany, 89081 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Genova, GE, Italy, 16132 Novartis Investigative Site Taormina, ME, Italy, 98039 Novartis Investigative Site Milano, MI, Italy, 20133 Novartis Investigative Site Padova, PD, Italy, 35100 Novartis Investigative Site Aviano, PN, Italy, 33081 Novartis Investigative Site Torino, TO, Italy, 10153 Collapse << |
| NCT01844765 | - | - | Active, not recruiting | - | - |
| NCT00750659 | Chronic Myeloid Leukemia ... more >> Acute Lymphoblastic Leukemia Stem Cell Transplantation Collapse << | Phase 2 | Completed | - | Israel ... more >> Chaim Sheba Medical Center Tel-Hashomer, Israel, 52621 Collapse << |
| NCT00129740 | Leukemia, Myelogenous, Chronic | Phase 2 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
| NCT01140568 | Glioma | Phase 2 | Terminated(Sponsor contract wa... more >>s not renewed by mutual decision of sponsor and PI.) Collapse << | - | United States, California ... more >> The Rebecca and John Moores UCSD Cancer Center La Jolla, California, United States, 92093 Collapse << |
| NCT01289028 | - | - | Completed | - | - |
| NCT01206088 | CML Nilotinib... more >> Imatinib Resistant Imatinib Intolerant Collapse << | Phase 4 | Completed | - | Korea, Republic of ... more >> St. Mary hospital, Catholic medical center Seoul, Korea, Republic of Collapse << |
| NCT02115386 | Philadelphia Positive (Ph+) Ch... more >>ronic Myeloid Leukemia Collapse << | Phase 3 | Completed | - | Russian Federation ... more >> Novartis Investigative Site Moscow, Russian Federation, 125167 Collapse << |
| NCT01261429 | Pigmented Villonodular Synovit... more >>is Collapse << | Phase 2 | Completed | - | France ... more >> Institut Bergonié Bordeaux, France Centre Oscar Lambret Lille, France Centre Léon Bérard Lyon, France Hôpital La Timone Marseille, France Institut Paoli Calmettes Marseille, France Institut Curie Paris, France Institut Claudius Regaud Toulouse, France Institut Gustave Roussy Villejuif, France Italy Istituto Nazionale dei Tumori Milano, Italy Regina Elena National Cancer Institute Roma, Italy Netherlands Leiden University Medical Center Leiden, Netherlands Radboud University Nijmegen Medical Centre Nijmegen, Netherlands Poland Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Warsaw, Poland United Kingdom University College Hospital UCL Hospitals NHS Foundation Trust London, United Kingdom Oxford Cancer Centre Oxford, United Kingdom Collapse << |
| NCT00844298 | Leukemia | Phase 2 | Completed | - | Korea, Republic of ... more >> Daegu Fatima Hospital Daegu, Korea, Republic of, 701-600 Kyungpook National University Hospital Daegu, Korea, Republic of, 702-701 Yeungnam University Medical Center Daegu, Korea, Republic of, 712-749 Daegu Catholic University Hospital Daegu, Korea, Republic of National Cancer Center - Korea Goyang, Korea, Republic of, 410-769 Chonnam National University Hwasun Hospital Jeollanam-do, Korea, Republic of, 519-809 Gyeongsang National University Hospital Jinju, Korea, Republic of, 660-701 Pusan National University Hospital Pusan, Korea, Republic of, 602-739 Inje University Seoul Paik Hospital Seoul, Korea, Republic of, 100-032 Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Kyung Hee University Hospital Seoul, Korea, Republic of, 130-702 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center - University of Ulsan College of Medicine Seoul, Korea, Republic of, 138-736 Konkuk University Medical Center Seoul, Korea, Republic of, 143-729 Ajou University Hospital Suwon, Korea, Republic of, 441-749 Ulsan University Hospital Ulsan, Korea, Republic of Collapse << |
| NCT00844298 | - | - | Completed | - | - |
| NCT01155817 | Bone Marrow Transplant Failure... more >> Lymphoma, Non-Hodgkin Lymphoma, T-Cell, Peripheral Collapse << | Phase 1 | Unknown | July 2014 | United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Colorado Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 Canada, British Columbia Gordon and Leslie Diamond Health Care Centre Hematology Administration Vancouver, British Columbia, Canada, V5Z1M9 Collapse << |
| NCT01657604 | Chronic Myeloid Leukemia | Phase 3 | Active, not recruiting | December 2022 | - |
| NCT00751036 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 3 | Terminated | - | - |
| NCT00633295 | Gastrointestinal Stromal Tumor... more >>s (GIST) Collapse << | Phase 2 | Completed | - | Israel ... more >> Novartis Investigative Site Jerusalem, Israel Novartis Investigative Site Tel Aviv, Israel Novartis Investigative Site Tel Hashomer, Israel Collapse << |
| NCT02272777 | Leukemia | Phase 3 | Completed | - | China, Guangdong ... more >> Novartis Investigative Site Guangzhou, Guangdong, China, 51000 Novartis Investigative Site Guangzhou, Guangdong, China, 510515 China, Hubei Novartis Investigative Site Wuhan, Hubei, China, 430022 China, Jiangsu Novartis Investigative Site Nanjing, Jiangsu, China, 210008 China, Sichuan Novartis Investigative Site Chengdu, Sichuan, China, 610041 China, Tianjin Novartis Investigative Site Tianjin, Tianjin, China, 300020 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310003 China Novartis Investigative Site Beijing, China, 100044 Novartis Investigative Site Fuzhou, China, 350001 Novartis Investigative Site Jinan, China, 250012 Novartis Investigative Site Shanghai, China, 200025 Novartis Investigative Site Shanghai, China, 200433 Collapse << |
| NCT01254188 | Chronic Myeloid Leukemia | Phase 3 | Completed | - | - |
| NCT01884922 | Refractory Low-grade Gliomas ... more >> Recurrent Low-grade Gliomas Collapse << | Phase 1 | Recruiting | May 2019 | Austria ... more >> Medical University of Vienna Not yet recruiting Vienna, Austria, A-1090 Contact: Amedeo AZIZI, MD amedeo.azizi@meduniwien.ac.at Principal Investigator: Amedeo AZIZI, MD Denmark Rigshospitalet Not yet recruiting Copenhagen, Denmark, DK - 2100 Contact: Karsten Nysom, MD-PhD 35 45 08 09 ext +45 karsten.nysom@regionh.dk Principal Investigator: Karsten Nysom, MD-PhD France Gustave Roussy Recruiting Villejuif, Val de Marne, France, 94805 Contact: Jacques GRILL, MD 0142116209 ext +33 jacques.grill@gustaveroussy.fr Contact: Rudiger HASSELBERG 0142116250 ext +33 rudiger.hasselberg@gustaveroussy.fr Principal Investigator: Jacques GRILL, MD Germany Koordinierungszentrum für Klinische Studien (KKS) der Charité Not yet recruiting Berlin, Germany, 13353 Contact: Pablo HERNAIZ-DRIEVER, MD pablo.hernaiz@charite.de Principal Investigator: Pablo HERNAIZ-DRIEVER, MD Italy University Hospital of Padua Not yet recruiting Padua, Italy, 35128 Contact: Enrico OPOCHER, MD eopocher@libero.it Principal Investigator: Enrico OPOCHER Netherlands Erasmus MC/Sophia Children's Hospital Not yet recruiting Rotterdam, Netherlands, 3015GJ Contact: IM van der Sluis, MD-PhD 10 703 6691 ext +31 i.vandersluis@erasmusmc.nl Principal Investigator: IM van der Sluis, MD-PhD Spain Fundació Sant Joan de Déu Not yet recruiting Esplugues del Llobregat (Barcelona), Spain, 08950 Contact: Ofelia Cruz, MD 93 253 21 14 ext +34 ocruz@hsjdbcn.org Principal Investigator: Ofelia Cruz, MD Switzerland Swiss Pediatric Oncology Group Not yet recruiting Bern, Switzerland, 3008 Contact: Nicolas Gerber, MD 44 266 31 17 ext +41 nicolas.gerber@kispi.uzh.ch Principal Investigator: Nicolas GERBER, MD United Kingdom Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham Not yet recruiting Edgbaston, Birmingham, United Kingdom, B15 2TT Contact: Susan PICTON, MD Susan.Picton@leedsth.nhs.uk Principal Investigator: Susan PICTON, MD Collapse << |
| NCT01254188 | - | - | Completed | - | - |
| NCT02353728 | Chronic Myeloid Leukemia | Phase 2 | Recruiting | January 2019 | United States, New York ... more >> Weill Cornell Medical College Recruiting New York, New York, United States, 10065 Contact: Tania Curcio 212-746-2571 tjc9003@med.cornell.edu Principal Investigator: Ellen Ritchie, MD Collapse << |
| NCT02774512 | Colon Cancer | Early Phase 1 | Withdrawn(none participant has... more >> been enrolled and recruited during the first year after competent autority autorisation.) Collapse << | November 2017 | France ... more >> Institut Bergonié Bordeaux, France, 33076 Collapse << |
| NCT01735955 | GIST and CML | Phase 4 | Recruiting | April 28, 2023 | - |
| NCT01179737 | Pulmonary Arterial Hypertensio... more >>n Collapse << | Phase 2 | Terminated(Study was terminate... more >>d due to serious adverse event (SAE)) Collapse << | - | United States, Massachusetts ... more >> Novartis Investigative Site Boston, Massachusetts, United States, 02118 United States, Michigan Novartis Investigative Site Ann Arbor, Michigan, United States, 48109-0391 United States, North Carolina Novartis Investigative Site Chapel Hill, North Carolina, United States, 27599 United States, Ohio Novartis Investigative Site Cleveland, Ohio, United States, 44195 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37232-2573 Canada, Alberta Novartis Investigative Site Calgary, Alberta, Canada, T6G 2B7 Germany Novartis Investigative Site Hamburg, Germany, 20246 Novartis Investigative Site Heidelberg, Germany, 69120 Novartis Investigative Site Marburg, Germany, 35039 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 120-752 Singapore Novartis Investigative Site Singapore, Singapore, 119074 Novartis Investigative Site Singapore, Singapore, 168752 Switzerland Novartis Investigative Site Zurich, Switzerland, 8091 Collapse << |
| NCT00756509 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 4 | Active, not recruiting | December 31, 2019 | Finland ... more >> Novartis Investigative Site HUS, Finland, FIN-00029 France Novartis Investigative Site Lyon Cedex, France, 69373 Germany Novartis Investigative Site Bad Saarow, Germany, 15526 Novartis Investigative Site Essen, Germany, 45147 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Muenchen, Germany, 81377 Italy Novartis Investigative Site Milano, MI, Italy, 20133 Spain Novartis Investigative Site Hospitalet de LLobregat, Cataluña, Spain, 08907 Novartis Investigative Site Valencia, Comunidad Valenciana, Spain, 46009 Novartis Investigative Site Palma De Mallorca, Islas Baleares, Spain, 07120 Collapse << |
| NCT00751036 | - | - | Terminated | - | - |
| NCT02225574 | Leukemia | Phase 1 | Terminated(Slow Accrual - Only... more >> 1 patient enrolled in Phase 1 - Study never went to Phase II) Collapse << | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
| NCT00471328 | - | - | Completed | - | - |
| NCT00782834 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 2 | Terminated(Stopped early for f... more >>utility, unable to meet accrual goals) Collapse << | - | United States, Pennsylvania ... more >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Collapse << |
| NCT00782834 | - | - | Terminated(Stopped early for f... more >>utility, unable to meet accrual goals) Collapse << | - | - |
| NCT00471328 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 3 | Completed | - | - |
| NCT01061177 | CML in Chronic Phase | Phase 4 | Completed | - | - |
| NCT01179737 | - | - | Terminated(Study was terminate... more >>d due to serious adverse event (SAE)) Collapse << | - | - |
| NCT02001818 | Chronic Myeloid Leukaemia | Phase 2 | Recruiting | December 2021 | Australia, South Australia ... more >> Royal Adelaide Hospital Recruiting Adelaide, South Australia, Australia, 5000 Contact: Tim Hughes, MBBS, MD,FRACP, FRCPA +61 8 822 3330 timothy.hughes@health.sa.gov.au Principal Investigator: Tim Hughes, MBBS, MD, FRACP, FRCPA Collapse << |
| NCT03228303 | Chronic Myeloid Leukemia | Early Phase 1 | Not yet recruiting | August 1, 2020 | - |
| NCT01061177 | - | - | Completed | - | - |
| NCT01099514 | Metastatic Melanoma With KIT A... more >>berration Collapse << | Phase 2 | Completed | - | Korea, Republic of ... more >> Samsung Cancer Center Seoul, Korea, Republic of Collapse << |
| NCT01043874 | Philadelphia Chromosome Positi... more >>ve Chronic Myelogenous Leukemia in Chronic Phase Collapse << | Phase 4 | Completed | - | Japan ... more >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 453-8511 Novartis Investigative Site Nagoya-city, Aichi, Japan, 466-8560 Novartis Investigative Site Nagoya, Aichi, Japan, 464-8681 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Kitakyushu, Fukuoka, Japan, 807-8556 Novartis Investigative Site Hiroshima-city, Hiroshima, Japan, 734-8551 Novartis Investigative Site Kumamoto City, Kumamoto, Japan, 860-8556 Novartis Investigative Site Sendai-city, Miyagi, Japan, 983-8520 Novartis Investigative Site Nagasaki-city, Nagasaki, Japan, 852-8501 Novartis Investigative Site Okayama-city, Okayama, Japan, 700-8558 Novartis Investigative Site Osaka-city, Osaka, Japan, 545-8586 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Novartis Investigative Site Suita-city, Osaka, Japan, 565-0871 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8519 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8655 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 160-0023 Novartis Investigative Site Aomori, Japan, 030-8553 Novartis Investigative Site Gifu, Japan, 501-1194 Novartis Investigative Site Kyoto, Japan, 602-8566 Novartis Investigative Site Saga, Japan, 849-8501 Collapse << |
| NCT01407198 | Chordoma | Phase 1 | Active, not recruiting | December 2019 | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Collapse << |
| NCT01223898 | Chronic Myeloid Leukemia | Phase 1 | Completed | - | Germany ... more >> Novartis Investigative Site Frankfurt/M, Germany, 60590 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Mannheim, Germany, 68167 Novartis Investigative Site Ulm, Germany, 89081 United Kingdom Novartis Investigative Site Glasgow, United Kingdom, G12 0YN Collapse << |
| NCT01605981 | Chronic Myeloid Leukemia (CML) | Phase 4 | Withdrawn | January 2017 | Brazil ... more >> Novartis Investigative Site Fortaleza, CE, Brazil, 60115-290 Novartis Investigative Site Goiania, GO, Brazil, 74605-020 Novartis Investigative Site Belo Horizonte, MG, Brazil, 30130-100 Novartis Investigative Site Cuiaba, MS, Brazil, 033426-102 Novartis Investigative Site Porto Alegre, Porto Alegre-RS, Brazil Novartis Investigative Site Curitiba, PR, Brazil, 80060-900 Novartis Investigative Site Niterói, RJ, Brazil, 24030210 Novartis Investigative Site Rio de Janeiro, RJ, Brazil, 20.211-030 Novartis Investigative Site Porto Alegre, RS, Brazil, 90035-903 Novartis Investigative Site São José, Sao Paulo, Brazil, 15015-110 Novartis Investigative Site Florianopolis, SC, Brazil, 88034-000 Novartis Investigative Site Campinas, SP, Brazil, 13083-970 Novartis Investigative Site Jaú, SP, Brazil, 17210-080 Novartis Investigative Site Santo Andre, SP, Brazil, 09190-615 Novartis Investigative Site Santos, SP, Brazil, 11075-350 Novartis Investigative Site São Paulo, SP, Brazil, 05651-901 Novartis Investigative Site São Paulo, SP, Brazil, 08270-070 Novartis Investigative Site Sao Paulo, Brazil, 03454-000 Collapse << |
| NCT01166139 | Systemic Sclerosis | Phase 2 | Completed | - | United States, New York ... more >> Hospital for Special Surgery New York, New York, United States, 10021 Collapse << |
| NCT01166139 | - | - | Completed | - | - |
| NCT01252017 | Patients Who Have Received All... more >>o-HSCT Collapse << | Phase 2 | Completed | - | Taiwan ... more >> National Taiwan University Hospital Taipei, Taiwan, 100 Collapse << |
| NCT01275586 | - | - | Completed | - | - |
| NCT01866553 | Chronic Myeloid Leukemia | Phase 2 | Terminated(insufficient enroll... more >>ment) Collapse << | - | Denmark ... more >> Aarhus University Hospital Aarhus, Denmark Finland Helsinki University Hospital Helsinki, Finland Netherlands VU University Medical Center Amsterdam, Netherlands Norway Trondheim University Hospital Trondheim, Norway Sweden Uppsala University Hospital Uppsala, Sweden Collapse << |
| NCT01043874 | - | - | Completed | - | - |
| NCT01400074 | Chronic Myeloid Leukemia | Phase 3 | Unknown | June 2014 | Korea, Republic of ... more >> Seoul St. Mary's Hospital Recruiting Seoul, Korea, Republic of, 137-701 Collapse << |
| NCT01275586 | Neurofibromatosis ... more >> NF1 Neurofibromas Collapse << | Early Phase 1 | Completed | - | United States, Indiana ... more >> Riley Hospital for Children Indianapolis, Indiana, United States, 46202 Collapse << |
| NCT00788775 | - | - | Completed | - | - |
| NCT03079505 | Chronic Myeloid Leukemia - Chr... more >>onic Phase Collapse << | Phase 3 | Recruiting | August 2022 | Qatar ... more >> National Center for Cancer Care & Research (NCCCR) Recruiting Doha, Qatar, 3050 Contact: Mohamed Yassin Contact: Abdulqadir Nashwan 0097466473549 anashwan@hamad.qa Collapse << |
| NCT02546674 | Chronic Myeloid Leukemia | Phase 4 | Recruiting | February 18, 2020 | - |
| NCT01819389 | Leukemia, Myeloid, Chronic, BC... more >>R-ABL Positive Collapse << | Phase 3 | Completed | - | Mexico ... more >> Servicio de Hematologia, Hospital Universitario "José E. Gonzalez" Monterrey, Nuevo Leon, Mexico, 64460 Collapse << |
| NCT01702064 | Chronic Phase Chronic Myeloid ... more >>Leukemia Collapse << | Phase 1 | Active, not recruiting | March 2019 | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Collapse << |
| NCT01456676 | Philadelphia Chromosome Positi... more >>ve Chronic Myelogenous Leukemia Collapse << | Phase 1 | Completed | - | Canada, Ontario ... more >> Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 France Novartis Investigative Site Marseille, France, 13273 Germany Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Ulm, Germany, 89081 Italy Novartis Investigative Site Roma, RM, Italy, 00161 Spain Novartis Investigative Site Pamplona, Navarra, Spain, 31008 Novartis Investigative Site Madrid, Spain, 28006 Collapse << |
| NCT01089595 | GIST Metastat... more >>ic Disease Collapse << | Phase 2 | Terminated(Novartis is ending ... more >>their research program for Nilotinib in GIST.) Collapse << | - | United States, Missouri ... more >> Siteman Cancer Center, Washington University School of Mediciine St Louis, Missouri, United States, 63110 United States, North Carolina Wake Forest University Winston-Salem, North Carolina, United States, 27157-1082 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Collapse << |
| NCT01528085 | Philadelphia Chromsome Positiv... more >>e Acute Lymphoblastic Leukemia Collapse << | Phase 2 | Unknown | November 2018 | - |
| NCT01270893 | Gastrointestinal Cancer | Phase 2 | Withdrawn(No particapnt recrui... more >>tment.) Collapse << | - | - |
| NCT00788775 | Mucosal Lentiginous Melanoma ... more >> Acral Melanoma Melanoma Collapse << | Phase 2 | Completed | - | United States, California ... more >> The Angeles Clinic and Research Institute Santa Monica, California, United States, 90404 United States, Colorado University of Colorado Aurora, Colorado, United States, 80045 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
| NCT02253277 | Chronic Myeloid Leukemia | Phase 1 Phase 2 | Completed | - | Germany ... more >> Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Mannheim, Germany, 68169 Collapse << |
| NCT01207492 | Pigmented Villonodular Synovit... more >>is Diffuse-type Giant Cell Tumor Tenosynovial Giant Cell Tumor Collapse << | Phase 2 | Active, not recruiting | December 2018 | United States, California ... more >> Sarcoma Oncology Center Santa Monica, California, United States, 90403 Stanford University Medical Center Stanford, California, United States, 94305 United States, Florida H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
| NCT01089595 | - | - | Terminated(Novartis is ending ... more >>their research program for Nilotinib in GIST.) Collapse << | - | - |
| NCT01207492 | - | - | Active, not recruiting | - | - |
| NCT01222143 | Acute Myeloid Leukemia | Phase 1 Phase 2 | Terminated | - | Canada, Ontario ... more >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
| NCT01784068 | Chronic Myelogenous Leukemia | Phase 2 | Recruiting | February 28, 2025 | - |
| NCT02108951 | Philidelphia Positive Chronic ... more >>Myeloid Leukaemia Collapse << | Phase 3 | Terminated(Study was terminate... more >>d because of slow recruitment) Collapse << | - | Australia, Australian Capital ... more >>Territory Novartis Investigative Site Canberra, Australian Capital Territory, Australia, 2605 Australia, New South Wales Novartis Investigative Site Kingswood, New South Wales, Australia, 2747 Novartis Investigative Site Kogarah, New South Wales, Australia, 2217 Novartis Investigative Site Liverpool, New South Wales, Australia, 2170 Novartis Investigative Site St. Leonards, New South Wales, Australia, 2065 Australia, Queensland Novartis Investigative Site Douglas, Queensland, Australia, 4810 Novartis Investigative Site Nambour, Queensland, Australia, 4560 Novartis Investigative Site South Brisbane, Queensland, Australia, 4101 Australia, South Australia Novartis Investigative Site Adelaide, South Australia, Australia, 5000 Australia, Victoria Novartis Investigative Site Fitzroy, Victoria, Australia, 3065 Novartis Investigative Site Geelong, Victoria, Australia, 3220 Novartis Investigative Site Melbourne, Victoria, Australia, 3000 Australia, Western Australia Novartis Investigative Site Murdoch, Western Australia, Australia, 6150 Novartis Investigative Site Nedlands, Western Australia, Australia, 6009 Collapse << |
| NCT02108951 | - | - | Terminated(Study was terminate... more >>d because of slow recruitment) Collapse << | - | - |
| NCT01743989 | Leukemia, Myeloid, Ph1-Positiv... more >>e Collapse << | Phase 3 | Recruiting | May 28, 2020 | - |
| NCT01395121 | Mucosal Lentiginous Melanoma ... more >> Acral Lentiginous Malignant Melanoma Collapse << | Phase 2 | Completed | - | United Kingdom ... more >> Royal Marsden NHS Foundation Trust London, United Kingdom, SW3 6JJ Collapse << |
| NCT00976612 | - | - | Completed | - | Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse << |
| NCT02917720 | Chronic Myeloid Leukemia | Phase 2 | Recruiting | May 2023 | Germany ... more >> Universitätsklinikum der RWTH Recruiting Aachen, Germany, 52074 Contact: Tim H. Brümmendorf, Dr. med. Klinikum Bayreuth Recruiting Bayreuth, Germany, 95445 Contact: Alexander Kiani, Dr. med. Vivantes Klinikum Neukölln Not yet recruiting Berlin, Germany, 12351 Contact: Maike de Wit, Dr. med. Klinikum Chemnitz Recruiting Chemnitz, Germany, 09113 Contact: Mathias Hänel, Dr. med. Onkologische Schwerpunktpraxis Not yet recruiting Esslingen, Germany, 73728 Contact: Robert Eckert, Dr. med. Centrum für Hämatologie und Onkologie Bethanien Recruiting Frankfurt, Germany, 60389 Contact: Hans Tesch, Dr. med. Schwerpunktpraxis Onkologie Recruiting Heilbronn, Germany, 74072 Contact: Jolanta Dengler, Dr. med. Universitätsklinikum Jena Recruiting Jena, Germany, 07740 Contact: Andreas Hochhaus Collapse << |
| NCT01863745 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 2 | Active, not recruiting | October 4, 2023 | Japan ... more >> Novartis Investigative Site Nagoya, Aichi, Japan, 464-8681 Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Gifu-city, Gifu, Japan, 501-1194 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8648 Novartis Investigative Site Yokohama-city, Kanagawa, Japan, 241-8515 Novartis Investigative Site Kumamoto City, Kumamoto, Japan, 860-8556 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-8574 Novartis Investigative Site Kurashiki, Okayama, Japan, 701-0192 Novartis Investigative Site Osaka-city, Osaka, Japan, 540-0006 Novartis Investigative Site Suita-city, Osaka, Japan, 565 0871 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0045 Collapse << |
| NCT02973711 | Leukemia, Chronic Myeloid | Phase 1 Phase 2 | Recruiting | April 2021 | United States, Michigan ... more >> The University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Patrick Burke, M.D. 734-647-8921 pwburke@umich.edu Principal Investigator: Patrick Burke, M.D. United States, North Carolina Wake Forest University Health Sciences Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Rupali Bhave, M.D. 336-713-0864 rbhave@wakehealth.edu Contact: Megan Brown-Farmer 336-713-6913 mebrown@wakehealth.edu Collapse << |
| NCT01131325 | CML Philadelp... more >>hia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels Collapse << | Phase 4 | Terminated | - | United States, Nevada ... more >> Comprehensive Cancer Centers of Nevada CCC of Nevada (1) Las Vegas, Nevada, United States, 89109 United States, Texas Cancer Center of the High Plains Amarillo, Texas, United States, 79106 Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2) Dallas, Texas, United States, 75246 Collapse << |
| NCT01914484 | Chronic Phase Chronic Myeloid ... more >>Leukemia Accelerated Phase Chronic Myeloid Leukemia Blastic Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia Resistant to Tyrosine Kinase Inhibitor Therapy Collapse << | Phase 1 Phase 2 | Unknown | July 2016 | Canada, Ontario ... more >> Princess Margaret Hospital / University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sima Bogomilsky, RN BScN CON(C) 416-946-4646 sima.bogomilsky@uhn.on.ca Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP 416-946-4501 ext 3449 sonal.malhotra@uhn.ca Principal Investigator: Dennis Kim, MD/PhD Sub-Investigator: Jeffrey H Lipton, MD/PhD Collapse << |
| NCT01810718 | Chronic Graft Versus Host Dise... more >>ase Collapse << | Phase 1 | Completed | - | Israel ... more >> Chaim Sheba Medical Center Tel Hashomer, Israel Italy Clinica di Ematologia - Ospedali Riuniti di Ancona Ancona, Italy S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle Cuneo, Italy Trapianti Midollo Osseo - Div. di Ematologia 2 - Ospedale S. Martino Genova, Italy Ospedale Panico Lecce, Italy Divisione di Ematologia - Istituto Nazionale dei Tumori Milano, Italy Ospedale Niguarda Ca' Grande Milano, Italy U.O. Ematologia I - Centro Trapianti di Midollo - Ospedale Maggiore - Policlinico Mangiagalli e Regina Elena Milano, Italy Ospedale San Carlo Potenza, Italy Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli Reggio Calabria, Italy Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza S. Giovanni Rotondo (FG), Italy Clinica Ematologica - AOU Santa Maria Della Misericordia Udine, Italy Collapse << |
| NCT00980018 | Chronic Myelogenous Leukemia | Phase 4 | Completed | - | United States, Arkansas ... more >> Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 Hematology Oncology Services of Arkansas SC Little Rock, Arkansas, United States, 72205 United States, California USC Norris Cancer Center LAC & USC Medical Center Los Angeles, California, United States, 90033 Southwest Cancer Care Murrieta Poway, California, United States, 92064 United States, Colorado Rocky Mountain Cancer Centers RMCC - Aurora Greenwood Village, Colorado, United States United States, Florida Florida Cancer Institute New Port Richey, Florida, United States, 34655 Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4 Ocoee, Florida, United States, *see dep* United States, Illinois Stroger Cook County Hospital John H. Stroger Hospital Chicago, Illinois, United States, 60612 United States, Indiana St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn Beech Grove, Indiana, United States, 46107 United States, Maryland St. Agnes Hospital Baltimore, Maryland, United States, 21229 United States, Missouri St. Louis University Cancer Center St. Louis, Missouri, United States, 63110 United States, Oregon Northwest Cancer Specialists Salmon Creek Office Portland, Oregon, United States, 97210 Oregon Health Sciences University Portland, Oregon, United States, 97239 United States, Tennessee The Jones Clinic Germantown, Tennessee, United States, 38138 United States, Texas Texas Oncology, P.A. Bedford, Texas, United States, 76022 Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp Dallas, Texas, United States, 75231 Texas Oncology Texas Oncology - Sugar Land Dallas, Texas, United States, 75246 MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77031 Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2) San Antonio, Texas, United States, 78229 Canada, Ontario Novartis Investigative Site Brampton, Ontario, Canada, L6R 3J7 Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 Novartis Investigative Site Montreal, Quebec, Canada, H3A 1A1 Collapse << |
| NCT01316250 | Chronic Myelogenous Leukemia | Not Applicable | Recruiting | January 2019 | Lebanon ... more >> American University of Beirut Medical Center Recruiting Beirut, Lebanon Contact: Ali Bazarbachi, MD, PhD 9613612434 bazarbac@aub.edu.lb Principal Investigator: Ali Bazarbachi, MD, PhD Collapse << |
| NCT02891395 | Graft Versus Host Disease | Phase 2 | Active, not recruiting | December 2018 | Belgium ... more >> CHU Sart Tilman Liège, Belgium France CHU d'Amiens Amiens, France CHU d'Angers Angers, France CHU Besançon Besancon, France CHU Bordeaux Bordeaux, France Hopital Morvan Brest, France CHU Clémenceau Caen, France HIA de Percy Clamart, France CHU de Clermont Ferrand Clermont Ferrand, France CHU Grenoble Grenoble, France Diseases of Blood Service HURIEZ hospital CHRU de LILLE LIlle, France, 59037 Centre hospitalier et régional de Lille Lille, France CHU de Lyon Lyon, France Institut Paoli Calmettes Marseille, France Hôpital Saint Eloi Montpellier, France CHU Hotel Dieu Nantes, France CHU de Nice Nice, France Hopital NECKER Paris, France Hôpital pitié Salpetrière Paris, France Centre Henri Becquerel Rouen, France CHU de STRASBOURG Strasbourg, France CHU Purpan Toulouse, France Collapse << |
| NCT01698905 | Chronic Myeloid Leukemia | Phase 2 | Active, not recruiting | February 6, 2025 | - |
| NCT02379416 | Solid Tumors | Phase 1 | Recruiting | November 19, 2020 | United States, Maryland ... more >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Collapse << |
| NCT03332511 | Chronic Myeloid Leukemia, Chro... more >>nic Phase Collapse << | Phase 4 | Completed | - | - |
| NCT01856283 | Leukemia, Myeloid, Chronic-Pha... more >>se Collapse << | Phase 2 | Active, not recruiting | June 2019 | Italy ... more >> A.O. Ospedale S. Antonio Gallarate, Milano, Italy Ospedale Desio- "Ospedale Civile" di Vimercate, Desio, Carate Brianza, Giussano, Seregno. Vimercate, Milano, Italy A.O di Circolo di Busto Arsizio Busto Arsizio, Varese, Italy Ospedali Riuniti Bergamo Bergamo, Italy Spedali Civili Brescia Brescia, Italy Ospedale Valduce Como, Italy Istituti Ospitalieri di Cremona Cremona, Italy A.O Ospedale Lecco Lecco, Italy Ospedale San Raffaele Milano, Italy, Italy A.O Sacco Milano, Italy Istituto dei Tumori Milano, Italy Istituto Europeo Oncologia Milano, Italy Ospedale Maggiore Policlinico Milano, Italy Ospedale S. Paolo Milano, Italy S. Gerardo di Monza Monza, Italy Policlinico S.Matteo Pavia Pavia, Italy A.O. Universitaria Fondazione Macchi Varese, Italy Collapse << |
| NCT01562847 | - | - | Unknown | June 2015 | Korea, Republic of ... more >> Seoul St. Mary's Hospital Seoul, Korea, Republic of, 137-701 Collapse << |
| NCT02281474 | Parkinson's Disease ... more >> Parkinson's Disease Dementia Diffuse Lewy Body Disease Collapse << | Phase 1 | Completed | - | United States, District of Col... more >>umbia MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007 Collapse << |
| NCT02201459 | Chronic Myeloid Leukemia | Phase 3 | Recruiting | August 2019 | France ... more >> Franck NICOLINI Recruiting Lyon, France, 04 78 86 22 50 Contact: Franck Nicolini, MD 4 78 86 22 50 ext 33 franck-emmanuel.nicolini@chu-lyon.fr Collapse << |
| NCT03764215 | Huntington Disease | Phase 1 | Recruiting | May 31, 2020 | United States, District of Col... more >>umbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Hope Heller 202-687-1366 hope.heller@gunet.georgetown.edu Contact: Robin Kuprewicz, MA rk1028@georgetown.edu Collapse << |
| NCT02086487 | Myeloid Leukemia, Chronic | Phase 4 | Terminated(Because of many uns... more >>een obstacles resulted in poor accrual, study is terminated.) Collapse << | - | Saudi Arabia ... more >> National Guard Hospital Riyadh, Central, Saudi Arabia, 11426 King Fahad specialist Hospital Dammam, Eastern, Saudi Arabia Collapse << |
| NCT02587169 | Retroperitoneal Liposarcoma ... more >> Retroperitoneal Leiomyosarcoma Chondrosarcoma Collapse << | Phase 1 Phase 2 | Unknown | December 2015 | Spain ... more >> Hospital Universitari Son Espases Recruiting Palma de Mallorca, Balearic Islands, Spain Contact: Javier Martín, MD, PhD +34 871205705 javier.martin@ssib.es Principal Investigator: Javier Martín, MD, PhD Hospital Infanta Cristina Recruiting Badajoz, Spain Contact: Ignacio Delgado, MD ignadelgado@hotmail.com Principal Investigator: Ignacio Delgado, MD Hospital Universitari Germans Trials i Pujol Recruiting Badalona, Spain Contact: Olatz Etxaniz, MD oetxaniz@iconcologia.net Principal Investigator: Olatz Etxaniz, MD Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain Contact: Antonio López-Pousa, MD alopezp@santpau.cat Principal Investigator: Antonio López-Pousa, MD Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain Contact: Claudia Valverde, MD cmvalver@vhebron.net Principal Investigator: Claudia Valverde, MD Hospital Provincial de Castellón Recruiting Castellón, Spain Contact: Ramón de las Peñas, MD ramon.delaspenas@hospital2000.net Principal Investigator: Ramón de las Peñas, MD Hospital Universitario de Canarias Recruiting La Laguna, Spain Contact: Josefina Cruz, MD jcruzjurado@gmail.com Principal Investigator: Josefina Cruz, MD Complejo Asistencial Universitario de León Recruiting León, Spain Contact: Luis Miguel de Sande, MD lmgdesande@hotmail.com Principal Investigator: Luis Miguel de Sande, MD Hospital Puerta de Hierro Recruiting Madrid, Spain Contact: Ricardo Cubedo, MD rcubedo@gmail.com Principal Investigator: Ricardo Cubedo, MD Hospital Universitario La Paz Recruiting Madrid, Spain Contact: Andrés Redondo, MD aredondo12@gmail.com Principal Investigator: Andrés Redondo, MD Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain Contact: Mª Ángeles Vaz, MD mavaz3@yahoo.es Principal Investigator: Mª Ángeles Vaz, MD Hospital Universitario Virgen de la Arrixaca Recruiting Murcia, Spain Contact: Jerónimo Martínez, MD jeronimo@seom.org Principal Investigator: Jerónimo Martínez, MD Complejo Hospitalario de Navarra Recruiting Pamplona, Spain Contact: Nuria Láinez, MD nuria.lainez.milagro@cfnavarra.es Principal Investigator: Nuria Láinez, MD Hospital Marqués de Valdecilla Recruiting Santander, Spain Contact: Ana de Juan, MD ajuan@humv.es Principal Investigator: Ana de Juan, MD Hospital Clínico Universitario de Santiago Recruiting Santiago de Compostela, Spain Contact: Yolanda Vidal, MD yvidalinsua@yahoo.es Principal Investigator: Yolanda Vidal, MD Hospital Virgen del Rocío Recruiting Sevilla, Spain Contact: Pilar Sancho, MD sanchomarquez@gmail.com Principal Investigator: Pilar Sancho, MD Hospital Virgen de la Salud Recruiting Toledo, Spain Contact: Javier Medina, MD boladiez39@yahoo.es Principal Investigator: Javier Medina, MD Instituto Valenciano de Oncología Recruiting Valencia, Spain Contact: Javier Lavernia, MD javilavernia@hotmail.com Principal Investigator: Javier Lavernia, MD Hospital Xeral Cies Recruiting Vigo, Spain Contact: Juan Antonio Carrasco, MD juan.antonio.carrasco.alvarez@sergas.es Principal Investigator: Juan Antonio Carrasco, MD Hospital Universitario Miguel Servet Recruiting Zaragoza, Spain Contact: Javier Martínez-Trufero, MD jmtrufero@seom.org Principal Investigator: Javier Martínez-Trufero, MD Collapse << |
| NCT01690065 | Chronic Myeloid Leukemia in My... more >>eloid Blast Crisis Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 2 | Recruiting | December 2019 | Korea, Republic of ... more >> Seoul St Mary's Hospital Recruiting Seoul, Korea, Republic of Contact: Dong-Wook Kim, M.D., Ph.D. dwkim@catholic.ac.kr Principal Investigator: Dong-Wook Kim, M.D., Ph.D. Ulsan University Hospital Recruiting Ulsan, Korea, Republic of, 682714 Principal Investigator: Hawk Kim, M.D., Ph.D. Sub-Investigator: Jae-Hoo Park, M.D., Ph.D. Sub-Investigator: Jae-Cheol Jo, M.D., Ph.D. Collapse << |
| NCT02954978 | Parkinson Disease ... more >> Parkinsons Disease With Dementia Collapse << | Phase 2 | Active, not recruiting | July 2020 | United States, District of Col... more >>umbia MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007 Collapse << |
| NCT02947893 | Alzheimer's Disease | Phase 2 | Recruiting | December 2019 | United States, District of Col... more >>umbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Ashot R Shekoyan, MD, PhD 202-687-7591 ars232@georgetown.edu Contact: Charbel E Moussa, MD, PhD 202-687-7328 cem46@georgetown.edu Principal Investigator: Scott R. Turner, MD, PhD Collapse << |
| 靶点 | Description | IC50 |
|---|---|---|
| Bcr-Abl | IC50:30nM |
